羟苯氨酮对戊巴比妥钠致心力衰竭的治疗作用  

THERAPEUTIC EFFECT OF A NOVEL INODILATOR OXYPHENAMONE ON EXPERIMENTAL HEART FAILURE INDUCED BY SODIUM PENTOBARBITAL

作　　者：范礼理[1] 孙丽红[1] 孙卓前[1] 黄世军 

机构地区：[1]中国医学科学院中国协和医科大学药物研究所

出　　处：《药学学报》1999年第2期103-108,共6页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金;国家医药管理局新药研究基金

摘　　要：目的：研究强心扩血管新药羟苯氨酮（ｏｘｙｐｈｅｎａｍｏｎｅ）对心力衰竭的治疗作用。方法：用多导生理仪与电磁流量计测定戊巴比妥钠致心力衰竭豚鼠、猫与狗的心脏血流动力学参数。结果：ｉｖ羟苯氨酮１～８ｍｇ·ｋｇ－１，剂量依赖性地增加心肌收缩力、左室收缩压、心输出量、心脏作功及冠状动脉血流量，其作用强度与磷酸二酯酶抑制剂（ＰＤＥＩ）氨力农（ａｍｒｉｎｏｎｅ）相似。而ＰＤＥＩ增加心率，易致心律失常，并继续降低血压；羟苯氨酮则减慢心率，使降低的血压上升。结论：羟苯氨酮能明显改善心衰动物的心脏功能，其作用优于ＰＤＥＩ，有可能发展成为治疗心力衰竭的新药。AIM: To study the therapeutic effect of oxyphenamone on heart failure. METHODS: An acute heart failure model was established by giving sodium pentobarbital iv at the dosage of 30～60 mg·kg -1 in guinea pigs, cats and dogs. RESULTS: Intravenous injection of oxyphenamone(1～8 mg·kg -1 ) dose dependently increased myocardial contractile force, left ventricular systolic pressure, ±d P /d t max , cardiac output, left ventricular work and the blood flow of the coronary and femoral arteries. The cardiotonic effect of oxyphenamone was similar to that of phosphodiesterase inhibitors(PDEI) amrinone and milrinone. The differences between these two agents include that oxyphenamone increases mean arterial pressure(MAP) and decreases heart rate(HR) in animals with heart failure, but PDEI induces inverse effects on MAP and HR and is prone to produce arrhythmia. CONCLUSION: The results suggest that oxyphenamone is more beneficial for the treatment of heart failure.

关 键 词：羟苯氨酮 心力衰竭 药物疗法 戊巴比妥钠 

分 类 号：R541.605[医药卫生—心血管疾病] R972.1[医药卫生—内科学]